- ENOB announced on June 14, 2021, that it has entered into a 29 million registered direct offering, improving its sustainability.
- Its Pre-IND request for a potential HIV cure has been approved by the FDA.
- On June 21, 2021, the company announced that they acquired an exclusive license for an Inhaled Treatment and Prevention Technology to potentially treat and prevent all variants of the Coronavirus.
- ENOB is expected to burn more cash in the coming years, but on the brighter side, institutions backed them up as they are starting to generate good results for their investors.
For further details see:
Enochian Biosciences: A Follow Through For An HIV Cure